DEEP KNOWING TO KEEP GROWING

ST. JULIAN’S - MALTA
16-18 MAY 2024

FINAL PROGRAMME
Imprint

Editorial / Publisher
European Academy of Dermatology and Venereology (EADV)
eadv.org

Publication date
May 2024

Further about the EADV Symposium
eadv.org/symposium

Internet access / Wi-Fi
Free Wi-Fi access will be available in the common areas of the venue and in the session rooms.

Network: EADV2024
Password: EADV2024

Official app
The EADV Symposium 2024 app will bring the EADV Symposium to your smartphone or tablet. The official app offers a tailor-made mobile overview of this scientific event.

[More information page 35]

Follow the EADV social media channels for news and updates!

Facebook
Instagram
LinkedIn
X (formerly Twitter)

Join the conversation using #EADVSymposium
# Table of contents

EADV President's welcome letter ......................................................................................................................................................................................... 4  
Welcome from the EADV Scientific Programming Committee ....................................................................................................................................................................................... 5  
The Academy ......................................................................................................................................................................................................................... 6  
Continuing Medical Education – Continuing Professional Development (CME-CPD) ................................................................................................. 9  
Abstract reviewers......................................................................................................................................................................................................... 10  
Thematic index ................................................................................................................................................................................................................ 11  
Scientific Programme ........................................................................................................................................................................................................ 13  
  Thursday, 16 May 2024 ........................................................................................................................................................................................................... 13  
  Friday, 17 May 2024 ........................................................................................................................................................................................................ 17  
  Saturday, 18 May 2024 ..................................................................................................................................................................................................... 24  
General information ........................................................................................................................................................................................................... 30  
  Onsite facilities ........................................................................................................................................................................................................ 30  
  Official language ..................................................................................................................................................................................................... 31  
  Scientific sessions .................................................................................................................................................................................................... 31  
  Certificates and accreditation .......................................................................................................................................................................................... 32  
  Abstract and e-Poster ................................................................................................................................................................................................ 32  
  Information for speakers ................................................................................................................................................................................................ 32  
  Other services ....................................................................................................................................................................................................... 33  
  First aid and emergency numbers ...................................................................................................................................................................... 33  
  Privacy ................................................................................................................................................................................................................. 34  
Official mobile app ..................................................................................................................................................................................................... 35  
The venue ......................................................................................................................................................................................................................... 36  
Venue floorplans ........................................................................................................................................................................................................... 37  
Registration .................................................................................................................................................................................................................. 41  
  EADV Symposium Ticket ...................................................................................................................................................................................... 41  
Networking Symposium .............................................................................................................................................................................................. 42  
Healthcare Professional information and definition .......................................................................................................................................................... 43  
Industry sessions .......................................................................................................................................................................................................... 45  
Satellite symposia .................................................................................................................................................................................................... 47  
Participating companies .................................................................................................................................................................................................. 51
Dear Colleagues and Friends,

Welcome to the European Academy of Dermatology and Venereology (EADV) Spring Symposium, taking place in Malta from 16-18 May 2024. As President of the EADV, I am deeply honoured to welcome you to this event.

Spring Symposia hold a special place in the EADV calendar, emphasizing our commitment to European inclusiveness while allowing for in-depth exploration of specific topics. For this much-anticipated event, we’ve chosen the picturesque backdrop of Malta.

The core values of our academy are beautifully embodied in our symposium’s theme, “Deep Knowing to Keep Growing.” We are dedicated to promoting continuous learning and growth in the ever-evolving field of dermatology and venereology. We firmly believe that by delving into the profound depths of our discipline, we can collectively advance and achieve new levels of understanding and expertise.

Our distinguished Scientific Programming Committee has diligently crafted a program that will captivate and inspire. We’ll delve into recent breakthroughs in translational dermatology, advanced treatment modalities, and emerging trends in patient care.

This symposium offers a unique opportunity to connect with specialists and colleagues from around the world who share your passion for dermatology and venereology. Together, we will experience a tailor-made programme covering valuable insights and the latest updates in crucial areas such as acne management, pigmentary disorders, atopic dermatitis, and paediatric dermatology.

I wholeheartedly look forward to hosting you on the beautiful island of Malta, where the synergy of knowledge and the spirit of collaboration will create an unforgettable experience. Our goals include deepening our understanding and cultivating enduring relationships that will continue to flourish long after the symposium concludes.

Narak dalwaqt f’Malta! Welcome to Malta!

Prof. Dr. Martin Röcken
2022-2024 President of the EADV
Welcome from the EADV Scientific Programming Committee

Dear Colleagues,

It is my pleasure to extend a warm welcome to you for the 2024 EADV Spring Symposium, set against the picturesque backdrop of the enchanting island of Malta.

We are excited to present a compelling programme designed to provide you with enriching opportunities to connect and stay abreast of the latest developments in dermatology across a diverse range of clinical topics. With over 25 educational sessions featuring more than 100 talks, the symposium is structured into three distinct tracks to cater to your specific interests.

Track one will feature our “Focus On” sessions, offering a full day of immersion and in-depth coverage of a hot topic in our discipline. The first topic will be “Dermatology of Migrants”, a subject of great relevance not only in Malta but also throughout Europe. The second topic will be atopic dermatitis, a disease that has witnessed significant advancements in recent years thanks to the development of new therapeutics.

Track two will feature our popular “What’s New” sessions, covering a range of compelling topics, including acne, hair disorders, surgery, and paediatric dermatology, among others.

Track three will be dedicated to interactive sessions, a new favourite of our Spring Symposium. You can engage in case presentations featuring clinical and dermoscopy images presented as quizzes, allowing you to test and enhance your skills. For the first time, we will showcase presentations of challenging cases from residents to faculty, providing a unique opportunity to learn and refresh clinical reasoning and problem-solving skills for your daily practice.

Finally, on Saturday morning, we will end our meeting with the traditional “Breaking News” session featuring the latest novelties from the past six months across all fields of our specialty.

We eagerly anticipate your presence in Malta, where together, we will explore, learn, and advance the frontiers of dermatology.

Michel Gilliet
Chair of the Scientific Programming Committee, EADV

Scientific Programming Committee:
Michel Gilliet, Jo Lambert, Paola Pasquali, Lidia Rudnicka, Eli Sprecher, Thrasyvoulos Tzellos
EADV is committed to building the international community that develops, shares, and adopts best practices within dermatology and venereology.

With over 9'500 members and an active community of more than 15'000 professionals around the world, our goal is to be the trusted source for proven scientific advancements and practices in the prevention, diagnosis, and treatment of skin and venereal diseases.

Skin and venereal diseases are continuously evolving, as are the science and practices for preventing, diagnosing, and treating them. Advancements are being made every day that have the potential to have a significant impact on the ongoing battle to improve skin and sexual health around the world. Enabling these advancements to be validated and ensuring all professionals adopt the best practices ultimately moves dermatology and venereology forward.

EADV and its international community of passionate professionals define and spread best practices in dermatology and venereology for the benefit of all. We are a true platform for collaboration and progress across borders and sub-specialties.

Expert task forces shape standards and develop best practice guidelines, while our events, publications, and educational courses share them with our members and the broader community so they can adopt them for maximum impact.

Our values

**COLLABORATIVE**
We believe in working together, capitalising on one another’s knowledge and expertise for the benefit of all.

**PROGRESSIVE**
We are always looking to improve, encouraging each other to change the way things are done for the better.

**INCLUSIVE**
We maintain that everybody has something to contribute, involving as many people as possible to maximise impact.

**TRUSTED**
We are professional, only sharing scientifically sound advancements so our members can move forward with confidence.
Our Activities

Our activities provide a unique platform to empower members to develop, spread and adopt best practices.

**CONGRESS**

Our flagship annual event showcases the latest science, research and best practices from all areas of dermato-venereology, with networking opportunities with colleagues from around the world.

**SYMPOSIUM**

Annual event focused on exploring the latest developments within specific areas of dermato-venereology, with networking opportunities with colleagues specialising in those areas.

**JEADV**

Leading international peer-reviewed journal with globally-recognized editorial board. Includes guidelines, reviews, clinical trials and original scientific articles.

**JEADV CLINICAL PRACTICE**

Open access peer-reviewed journal with cutting-edge clinical content of a more practical and hands-on nature.

**LEARNING**

Extensive range of face-to-face and online courses, offering continuous medical education, including a CME accredited programme, for trainees and practicing dermato-venereologists.

**GUIDELINES**

Over 30 task forces, open to all members, focusing on the creation and spreading of best practice guidelines for the prevention, diagnosis and treatment of skin and venereal diseases.

**NEWS**

Quarterly update on what is happening within our community, and in the field of dermato-venereology around the world, with particular emphasis on the latest best practices.

**FUNDING**

A range of activities and opportunities for community members to get involved or participate in, including scholarships, grants, research funding and fellowships in prestigious hospitals.
EADV MEMBERSHIP

EXCLUSIVE BENEFITS AWAIT YOU

Over 9'500 specialists, residents, scientists, medical students and nurses have already joined the EADV Community

Join the EADV Community today!
Applications and renewals for 2024 are open! We look forward to having you onboard

Questions? Contact us at membership@eadv.org
The EADV Symposium 2024, St Julian's - Malta, 16/05/2024 - 18/05/2024, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 14.5 European CME credits (ECMEC®s).

CME credits

Each medical specialist can claim only those hours of credit actually spent in the educational activity (as recorded by the scanning process).

Here below please find the breakdown of credits per day:

<table>
<thead>
<tr>
<th>Day</th>
<th>Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday, 16 May 2024</td>
<td>4</td>
</tr>
<tr>
<td>Friday, 17 May 2024</td>
<td>6</td>
</tr>
<tr>
<td>Saturday, 18 May 2024</td>
<td>4.5</td>
</tr>
</tbody>
</table>

The accreditation system is based on 1 ECMEC per hour.

No credits will be provided by the EADV to delegates participating in sessions organised by industry.

Procedure to gain your credits

Scan your badge, complete the evaluation forms and download the CME-CPD Certificate.

The EADV offers individual CME-CPD participation through the scanning of the bar code and the speaker/session evaluation that will be available until Saturday, 31 August 2024.

1. **Scan your badge** as you pass through the entrance of each session hall.
2. **Complete the anonymous online evaluation** for each attended session. Access the evaluation system via the CME/CPD accreditation page (available soon).
3. **Download your CME-CPD certificate** and retain it for your personal records.

Evaluation data is essential to our statistics and is of considerable help in the choice of future topics and speakers. Your feedback and comments are greatly appreciated.

Conversion of Credits

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [https://edhub.ama-assn.org/pages/applications](https://edhub.ama-assn.org/pages/applications).

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Information regarding the conversion of EACCME® credits

Credit will be converted based on one (1) hour of participation equalling one credit for all activities. Physicians wishing to convert EACCME® credits to AMA PRA Category 1 Credit™ will be required to access the AMA website at [https://edhub.ama-assn.org/pages/applications](https://edhub.ama-assn.org/pages/applications) to obtain the necessary paperwork and instructions. Physicians and other health care professionals will be required to pay a processing fee to the AMA.

For other countries, please contact the relevant national/regional accreditation authority.
Abstract reviewers

EADV is grateful to the following reviewers who have given their time and expertise in reviewing the submitted abstracts:

Zsuzsanna Bata-Csorgo (Hungary)  Rodica Olteanu (Romania)
Johann Bauer (Austria)  Valeska Padovese (Malta)
Aslı Bilgic (Türkiye)  David Pesqué (Spain)
Jose-Manuel Carrascosa (Spain)  Sandra Peternel (Croatia)
Pavel Chernyshov (Ukraine)  Asja Prohic (Bosnia and Herzegovina)
Zsanett Renáta Csoma (Hungary)  Adam Reich (Poland)
Dario Didona (Germany)  Mahtab Samimi (France)
Nejib Doss (Tunisia)  Mihael Skerlev (Croatia)
Kossara Drenovska (Bulgaria)  Luis Miguel Soares de Almeida (Portugal)
Klaus Fritz (Germany)  Pietro Sollena (Italy)
Ana Giménez-Arnau (Spain)  Efthymia Soura (Greece)
Jürg Hafner (Switzerland)  Sundaramoorthy Srinivasan (India)
Claudia Heller-Vitouch (Austria)  Zsuzsanna Szalai (Hungary)
Barbara Horvath (Netherlands)  Kaisa Tasanen (Finland)
Alexander Katoulis (Greece)  Tiago Torres (Portugal)
Jana Kazandjieva (Bulgaria)  Christian Vestergaard (Denmark)
Kateryna Kolyadenko (Ukraine)  Norbert Wikonkal (Hungary)
Dimitra Koumaki (Greece)  Torsten Zuberbier (Germany)
Arjen Fokko Nikkels (Belgium)
# Thematic index

<table>
<thead>
<tr>
<th>CODE</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>TIME</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>D1T01.1</td>
<td>Acne and related disorders, hidradenitis suppurativa</td>
<td>16.05</td>
<td>14.00 - 15.30</td>
<td>Grand Masters Suite</td>
</tr>
<tr>
<td></td>
<td><strong>Atopic dermatitis/eczema</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D1T02.1</td>
<td>Focus on Atopic dermatitis: Pathogenesis</td>
<td>16.05</td>
<td>14.00 - 15.30</td>
<td>Portomaso Suite</td>
</tr>
<tr>
<td>D1T02.2</td>
<td>Focus on Atopic dermatitis: Clinical subtypes</td>
<td>16.05</td>
<td>15.45 - 17.15</td>
<td>Portomaso Suite</td>
</tr>
<tr>
<td>D2T03.1</td>
<td>Focus on Atopic dermatitis: Comorbidities</td>
<td>17.05</td>
<td>09.00 - 10.30</td>
<td>Spinola Suite</td>
</tr>
<tr>
<td>D2T03.2</td>
<td>Focus on Atopic dermatitis: Therapies</td>
<td>17.05</td>
<td>10.45 - 12.15</td>
<td>Spinola Suite</td>
</tr>
<tr>
<td></td>
<td><strong>Breaking news</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D3T01.1</td>
<td>Breaking news</td>
<td>18.05</td>
<td>09.00 - 10.30</td>
<td>Grand Masters Suite</td>
</tr>
<tr>
<td>D3T01.2</td>
<td>Breaking news</td>
<td>18.05</td>
<td>10.45 - 12.15</td>
<td>Grand Masters Suite</td>
</tr>
<tr>
<td>D3T01.3</td>
<td>Breaking news</td>
<td>18.05</td>
<td>12.30 - 14.00</td>
<td>Grand Masters Suite</td>
</tr>
<tr>
<td></td>
<td><strong>Bullous diseases</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D3T03.3</td>
<td>What's new in: Bullous diseases</td>
<td>18.05</td>
<td>12.30 - 14.00</td>
<td>Spinola Suite</td>
</tr>
<tr>
<td></td>
<td><strong>Clinical cases</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D2T02.1</td>
<td>From clinical and dermatoscopic diagnosis to management</td>
<td>17.05</td>
<td>09.00 - 10.30</td>
<td>Portomaso Suite</td>
</tr>
<tr>
<td>D2T02.2</td>
<td>From clinical and dermatoscopic diagnosis to management</td>
<td>17.05</td>
<td>10.45 - 12.15</td>
<td>Portomaso Suite</td>
</tr>
<tr>
<td>D2T02.3</td>
<td>STIs - clues and pitfalls in your practice</td>
<td>17.05</td>
<td>14.00 - 15.30</td>
<td>Portomaso Suite</td>
</tr>
<tr>
<td>D2T02.4</td>
<td>Clinical reasoning: Residents quiz the faculty</td>
<td>17.05</td>
<td>15.45 - 17.15</td>
<td>Portomaso Suite</td>
</tr>
<tr>
<td></td>
<td><strong>Cutaneous oncology</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D2T01.3</td>
<td>What's new in: Melanoma</td>
<td>17.05</td>
<td>14.00 - 15.30</td>
<td>Grand Masters Suite</td>
</tr>
<tr>
<td></td>
<td><strong>Dermatological surgery</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D2T01.1</td>
<td>What's new in: Surgical procedures</td>
<td>17.05</td>
<td>09.00 - 10.30</td>
<td>Grand Masters Suite</td>
</tr>
<tr>
<td></td>
<td><strong>Dermoscopy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D2T02.1</td>
<td>From clinical and dermatoscopic diagnosis to management</td>
<td>17.05</td>
<td>09.00 - 10.30</td>
<td>Portomaso Suite</td>
</tr>
<tr>
<td>D2T02.2</td>
<td>From clinical and dermatoscopic diagnosis to management</td>
<td>17.05</td>
<td>10.45 - 12.15</td>
<td>Portomaso Suite</td>
</tr>
</tbody>
</table>

Focus on | What's new | Plenary session | Free communications | Interactive clinical cases | Breaking news
<table>
<thead>
<tr>
<th>CODE</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>TIME</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>D2T01.4</td>
<td>Diagnostic procedures: What’s new in: Imaging techniques</td>
<td>17.05</td>
<td>15.45 - 17.15</td>
<td>Grand Masters Suite</td>
</tr>
<tr>
<td></td>
<td>Hair disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D3T02.1</td>
<td>Hair disorders</td>
<td>18.05</td>
<td>09.00 - 10.30</td>
<td>Portomaso Suite</td>
</tr>
<tr>
<td></td>
<td>Infectious diseases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PL</td>
<td>Plenary session</td>
<td>16.05</td>
<td>17.30 - 18.30</td>
<td>Grand Masters Suite</td>
</tr>
<tr>
<td></td>
<td>Migrant dermatology and venereology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D3T03.1</td>
<td>Focus on migrant dermatology and venereology: Climate change and migration</td>
<td>18.05</td>
<td>09.00 - 10.30</td>
<td>Spinola Suite</td>
</tr>
<tr>
<td></td>
<td>Focus on migrant dermatology and venereology: Skin signs of violence and torture</td>
<td>18.05</td>
<td>10.45 - 12.15</td>
<td>Spinola Suite</td>
</tr>
<tr>
<td>D2T03.3</td>
<td>Focus on migrant dermatology and venereology: Diversity in dermatological care</td>
<td>17.05</td>
<td>12.30 - 14.00</td>
<td>Spinola Suite</td>
</tr>
<tr>
<td></td>
<td>Miscellaneous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FC01</td>
<td>Free communications 1</td>
<td>16.05</td>
<td>14.00 - 15.30</td>
<td>Spinola Suite</td>
</tr>
<tr>
<td>FC02</td>
<td>Free communications 2</td>
<td>16.05</td>
<td>15.45 - 17.15</td>
<td>Spinola Suite</td>
</tr>
<tr>
<td>D1T01.2</td>
<td>What’s new in: Island dermatology</td>
<td>16.05</td>
<td>15.45 - 17.15</td>
<td>Grand Masters Suite</td>
</tr>
<tr>
<td></td>
<td>Paediatric dermatology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D3T02.2</td>
<td>What’s new in: Paediatric dermatology</td>
<td>18.05</td>
<td>10.45 - 12.15</td>
<td>Portomaso Suite</td>
</tr>
<tr>
<td></td>
<td>Pigmentary disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D2T01.2</td>
<td>What’s new in: Pigmentary disorders and photoprotection</td>
<td>17.05</td>
<td>10.45 - 12.15</td>
<td>Grand Masters Suite</td>
</tr>
<tr>
<td></td>
<td>Pruritus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D3T02.3</td>
<td>What’s new in: Pruritus and prurigo</td>
<td>18.05</td>
<td>12.30 - 14.00</td>
<td>Portomaso Suite</td>
</tr>
<tr>
<td></td>
<td>Sexually transmitted infections, HIV/AIDS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D2T02.3</td>
<td>STIs - clues and pitfalls in your practice</td>
<td>17.05</td>
<td>14.00 - 15.30</td>
<td>Portomaso Suite</td>
</tr>
<tr>
<td>D2T03.4</td>
<td>Focus on migrant dermatology and venereology: STIs in migrants</td>
<td>17.05</td>
<td>15.45 - 17.15</td>
<td>Spinola Suite</td>
</tr>
</tbody>
</table>
Scientific Programme

Thursday, 16 May 2024

<table>
<thead>
<tr>
<th>ROOM</th>
<th>GRAND MASTERS SUITE</th>
<th>PORTOMASO SUITE</th>
<th>SPINOLA SUITE</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 15:30</td>
<td>What’s new in: Acne</td>
<td>Focus on Atopic dermatitis: Pathogenesis</td>
<td>Free communications 1</td>
</tr>
<tr>
<td>15:45 - 17:15</td>
<td>What’s new in: Island dermatology</td>
<td>Focus on Atopic dermatitis: Clinical subtypes</td>
<td>Free communications 2</td>
</tr>
<tr>
<td>17:30 - 18:30</td>
<td>Plenary session</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Focus on:** These sessions aim at providing comprehensive in-depth coverage of a certain topic in dermatology. The talks will be included in sessions on pathophysiology/epidemiology, clinical challenges, or practical aspects of disease management and will provide the latest cutting-edge information.

**What’s new:** These sessions will enable participants to update their knowledge on a specific topic and hear about the most relevant and recent developments, guidelines and practical knowledge from the past year. The talks will summarize the current understanding of the subject, followed by an update on the most recent novelties with their impact on clinical practice.

**Free communications:** Authors of the most highly ranked abstracts assessed by a selected panel of abstract reviewers are invited to provide a 10-minute oral presentation.

**Plenary sessions:** The Plenary lectures are EADV show-case sessions and include key-note lectures delivered by eminent scientists and doctors.

**Interactive clinical cases:** These lectures focus on a specific disease and include basic information about epidemiology, pathophysiology, diagnosis, management and prognosis. The target audience of these sessions is young dermatology trainees and residents, as well as dermatologists that want to refresh their basic knowledge on specific topics. The topic of each presentation should be developed from clinical cases and include clinical photographs. The main objective is to provide the audience clues for differential diagnosis and disease management in their daily practice. Each presentation is supposed to be interactive, with multiple-choice question made to the audience in accordance with the subjects treated in the talks. Each speaker will be asked to include 2-3 questions by “data” along with the different answers’ options.

**Breaking news:** This session type provides an update in rapidly changing fields of dermatology. It is a critical analysis of published data of last years, including new relevant information and latest development. The objective is to provide new clinically relevant and practical applicable information to be used in daily practice.
## Thursday, 16 May 2024

### WHAT'S NEW

#### GRAND MASTERS SUITE

**D1T01.1**  14:00 - 15:30  
**What's new in: Acne**

| Chairs: | Monika Arenbergerova (Prague, Czech Republic)  
|         | Clio Dessinioti (Athens, Greece) |

**D1T01.1A**  14:00  
Management of active acne and acne scars with lasers and light therapy

Brunilda Bardhi (Tirana, Albania)

**D1T01.1B**  14:20  
Infantile and pre-pubertal acne

Clio Dessinioti (Athens, Greece)

**D1T01.1C**  14:40  
A new look for the "old" isotretinoin

Bodo Melnik (Osnabrück, Germany)

**D1T01.1D**  15:00  
Diet and dietary supplement in acne

Monika Arenbergerova (Prague, Czech Republic)

**D1T01.1E**  15:20  
Discussion, Q&A

---

### WHAT'S NEW

##### GRAND MASTERS SUITE

**D1T01.2**  15:45 - 17:15  
**What's new in: Island dermatology**

| Chairs: | Lawrence Scerri (Kappara, Malta)  
|         | Menno Gaastra (Alkmaar, Netherlands) |

**D1T01.2A**  15:45  
Management of stings and bites

Lawrence Scerri (Kappara, Malta)

**D1T01.2B**  16:05  
Water-related infectious diseases

Eric Caumes (Paris, France)

**D1T01.2C**  16:25  
Water-induced dermatoses

Robert Corso (London, United Kingdom)

**D1T01.2D**  16:45  
Aquatic sports dermatoses

Menno Gaastra (Alkmaar, Netherlands)

**D1T01.2E**  17:05  
Discussion, Q&A
### Thursday, 16 May 2024

**FOCUS ON PORTOMASO SUITE**

| DIT02.1 | 14:00 - 15:30 | **Focus on Atopic dermatitis: Pathogenesis**  
Chairs: Jan Gutermuth (Brussels, Belgium)  
Roni Dodiuk-Gad (Haifa, Israel) |
|---------|---------------|-------------------------------------------------|
| DIT02.1A | 14:00 | **Epidemiology and pathophysiology**  
Jan Gutermuth (Brussels, Belgium) |
| DIT02.1B | 14:20 | **Skin barrier and microbiome**  
Antti Ilmari Lauerman (Helsinki, Finland) |
| DIT02.1C | 14:40 | **The metabolome in atopic dermatitis**  
Helen Alexander (London, United Kingdom) |
| DIT02.1D | 15:00 | **Environmental factors influencing the disease course**  
Roni Dodiuk-Gad (Haifa, Israel) |
| DIT02.1E | 15:20 | **Discussion, Q&A** |

| DIT02.2 | 15:45 - 17:15 | **Focus on Atopic dermatitis: Clinical subtypes**  
Chairs: Giovanni Damiani (Milan, Italy)  
Marie-Louise Schuttelaar (Groningen, Netherlands) |
|---------|---------------|-------------------------------------------------|
| DIT02.2A | 15:45 | **Late onset atopic dermatitis**  
Peter Schmid-Grendelmeier (Zurich, Switzerland) |
| DIT02.2B | 16:05 | **Head and neck dermatitis**  
Giovanni Damiani (Milan, Italy) |
| DIT02.2C | 16:25 | **Palmoplantar eczema**  
Marie-Louise Schuttelaar (Groningen, Netherlands) |
| DIT02.2D | 16:45 | **Nummular eczema**  
Natalie Garzorz-Stark (Munich, Germany) |
| DIT02.2E | 17:05 | **Discussion, Q&A** |
### Thursday, 16 May 2024

<table>
<thead>
<tr>
<th><strong>FREE COMMUNICATION</strong></th>
<th><strong>SPINOLA SUITE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FC01</strong></td>
<td>14:00 - 15:30</td>
</tr>
<tr>
<td></td>
<td><strong>FC02</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>PLENARY SESSION</strong></th>
<th><strong>GRAND MASTERS SUITE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PL</strong></td>
<td>17:30 - 18:30</td>
</tr>
<tr>
<td></td>
<td>17:30</td>
</tr>
<tr>
<td></td>
<td>17:45</td>
</tr>
<tr>
<td><strong>PL-01</strong></td>
<td>17:50</td>
</tr>
</tbody>
</table>
# Scientific Programme

## Friday, 17 May 2024

<table>
<thead>
<tr>
<th>ROOM</th>
<th>GRAND MASTERS SUITE</th>
<th>PORTOMASO SUITE</th>
<th>SPINOLA SUITE</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td></td>
<td>From clinical and dermatoscopic diagnosis to management</td>
<td>Focus on Atopic dermatitis: Comorbidities</td>
</tr>
<tr>
<td>10:30</td>
<td>What’s new in: Surgical procedures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td>From clinical and dermatoscopic diagnosis to management</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>What’s new in: Pigmentary disorders</td>
<td></td>
<td>Focus on Atopic dermatitis: Therapies</td>
</tr>
<tr>
<td>12:15</td>
<td>and photoprotection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>What’s new in: Melanoma</td>
<td>STIs – clues and pitfalls in your practice</td>
<td>Focus on migrant dermatology and venereology: Diversity in dermatological care</td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>What’s new in: Imaging techniques</td>
<td>Clinical reasoning: Residents quiz the faculty</td>
<td>Focus on migrant dermatology and venereology: STIs in migrants</td>
</tr>
<tr>
<td>17:15</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Focus on:** These sessions aim at providing comprehensive in-depth coverage of a certain topic in dermatology. The talks will be included in sessions on pathophysiology/epidemiology, clinical challenges, or practical aspects of disease management and will provide the latest cutting-edge information.

**What’s new:** These sessions will enable participants to update their knowledge on a specific topic and hear about the most relevant and recent developments, guidelines and practical knowledge from the past year. The talks will summarize the current understanding of the subject, followed by an update on the most recent novelties with their impact on clinical practice.

**Free communications:** Authors of the most highly ranked abstracts assessed by a selected panel of abstract reviewers are invited to provide a 10-minute oral presentation.

**Plenary sessions:** The Plenary lectures are EADV show-case sessions and include key-note lectures delivered by eminent scientists and doctors.

**Interactive clinical cases:** These lectures focus on a specific disease and include basic information about epidemiology, pathophysiology, diagnosis, management and prognosis. The target audience of these sessions is young dermatology trainees and residents, as well as dermatologists that want to refresh their basic knowledge on specific topics. The topic of each presentation should be developed from clinical cases and include clinical photographs. The main objective is to provide the audience clues for differential diagnosis and disease management in their daily practice. Each presentation is supposed to be interactive, with multiple-choice question made to the audience in accordance with the subjects treated in the talks. Each speaker will be asked to include 2-3 questions by "data" along with the different answers’ options.

**Breaking news:** This session type provides an update in rapidly changing fields of dermatology. It is a critical analysis of published data of last years, including new relevant information and latest development. The objective is to provide new clinically relevant and practical applicable information to be used in daily practice.
## WHAT'S NEW

### GRAND MASTERS SUITE

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Chairs</th>
</tr>
</thead>
</table>
| **D2T01.1** 09:00 - 10:30 | **What's new in: Surgical procedures**  
Chairs: Aleksandar Krunic (Chicago, United States)  
François Kuonen (Lausanne, Switzerland) | |
| **D2T01.1A** 09:00 | Imaging-assisted surgery  
François Kuonen (Lausanne, Switzerland) | |
| **D2T01.1B** 09:20 | Expanding the spectrum of Mohs surgery indications  
Aleksandar Krunic (Chicago, United States) | |
| **D2T01.1C** 09:40 | Surgical approach to dermatofibrosarcoma protuberans  
Nikolaos Vassos (Athens, Greece) | |
| **D2T01.1D** 10:00 | Understanding and following patients' preferences  
Azael Freites Martinez (Madrid, Spain) | |
| **D2T01.1E** 10:20 | Discussion, Q&A | |

## WHAT'S NEW

### GRAND MASTERS SUITE

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Chairs</th>
</tr>
</thead>
</table>
| **D2T01.2** 10:45 - 12:15 | **What's new in: Pigmentary disorders and photoprotection**  
Chairs: Mauro Picardo (Rome, Italy)  
Jelena Stojkovic-Filipovic (Belgrade, Serbia) | |
| **D2T01.2A** 10:45 | Management of vitiligo  
Jose Luis Lopez-Estebananz (Madrid, Spain) | |
| **D2T01.2B** 11:05 | Management of melasma  
Mauro Picardo (Rome, Italy) | |
| **D2T01.2C** 11:25 | Photoprotection according to skin phototype  
Yolanda Gilaberte Calzada (Zaragoza, Spain) | |
| **D2T01.2D** 11:45 | Difficult to treat hyperpigmentation  
Jelena Stojkovic-Filipovic (Belgrade, Serbia) | |
| **D2T01.2E** 12:05 | Discussion, Q&A | |
### WHAT'S NEW

**GRAND MASTERS SUITE**

#### D2T01.3 14:00 - 15:30

**What's new in: Melanoma**

**Chairs:** Mette Mogensen (Copenhagen, Denmark)  
Eduardo Nagore (Valencia, Spain)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td><strong>New imaging trends for diagnosis and follow-up</strong></td>
</tr>
<tr>
<td></td>
<td>Mette Mogensen (Copenhagen, Denmark)</td>
</tr>
<tr>
<td>14:20</td>
<td><strong>Safety margins and sentinel lymphnode biopsy</strong></td>
</tr>
<tr>
<td></td>
<td>Eduardo Nagore (Valencia, Spain)</td>
</tr>
<tr>
<td>14:40</td>
<td><strong>Adjuvant and neoadjuvant treatment</strong></td>
</tr>
<tr>
<td></td>
<td>Petr Arenberger (Prague, Czech Republic)</td>
</tr>
<tr>
<td>15:00</td>
<td><strong>Systemic treatment for advanced melanoma</strong></td>
</tr>
<tr>
<td></td>
<td>Daniel Micallef (Dingli, Malta)</td>
</tr>
<tr>
<td>15:20</td>
<td><strong>Discussion, Q&amp;A</strong></td>
</tr>
</tbody>
</table>

#### D2T01.4 15:45 - 17:15

**What's new in: Imaging techniques**

**Chairs:** Paola Pasquali (Cambrils, Spain)  
Mariano Suppa (Brussels, Belgium)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:45</td>
<td><strong>High-frequency ultrasound (HFUS)</strong></td>
</tr>
<tr>
<td></td>
<td>Norbert Kiss (Budapest, Hungary)</td>
</tr>
<tr>
<td>16:05</td>
<td><strong>Line-field confocal optical coherence tomography (LC-OCT)</strong></td>
</tr>
<tr>
<td></td>
<td>Mariano Suppa (Brussels, Belgium)</td>
</tr>
<tr>
<td>16:25</td>
<td><strong>Confocal microscopy</strong></td>
</tr>
<tr>
<td></td>
<td>Melissa Gill (Brooklyn, United States)</td>
</tr>
<tr>
<td>16:45</td>
<td><strong>Medical photography</strong></td>
</tr>
<tr>
<td></td>
<td>Paola Pasquali (Cambrils, Spain)</td>
</tr>
<tr>
<td>17:05</td>
<td><strong>Discussion, Q&amp;A</strong></td>
</tr>
</tbody>
</table>
# INTERACTIVE CLINICAL CASES

## PORTOMASO SUITE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>D2T02.1</strong></td>
<td>09:00 - 10:30</td>
<td>From clinical and dermatoscopic diagnosis to management</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairs: Aimilios Lallas (Thessaloniki, Greece)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ana-Maria Forsea (Bucharest, Romania)</td>
</tr>
<tr>
<td><strong>D2T02.1A</strong></td>
<td>09:00</td>
<td>Spitzoid lesions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aimilios Lallas (Thessaloniki, Greece)</td>
</tr>
<tr>
<td><strong>D2T02.1B</strong></td>
<td>09:20</td>
<td>Early melanoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ana-Maria Forsea (Bucharest, Romania)</td>
</tr>
<tr>
<td><strong>D2T02.1C</strong></td>
<td>09:40</td>
<td>Amelanotic melanoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Danica Tiodorovic (Nis, Serbia)</td>
</tr>
<tr>
<td><strong>D2T02.1D</strong></td>
<td>10:00</td>
<td>Melanoma in special locations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Giulia Briatico (Naples, Italy)</td>
</tr>
<tr>
<td><strong>D2T02.1E</strong></td>
<td>10:20</td>
<td>Discussion, Q&amp;A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>D2T02.2</strong></td>
<td>10:45 - 12:15</td>
<td>From clinical and dermatoscopic diagnosis to management</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chairs: Zoe Apalla (Thessaloniki, Greece)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mahtab Samimi (Tours, France)</td>
</tr>
<tr>
<td><strong>D2T02.2A</strong></td>
<td>10:45</td>
<td>Actinic keratosis and squamous cell carcinoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zoe Apalla (Thessaloniki, Greece)</td>
</tr>
<tr>
<td><strong>D2T02.2B</strong></td>
<td>11:05</td>
<td>Basal cell carcinoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Marek Pásek (Prague, Czech Republic)</td>
</tr>
<tr>
<td><strong>D2T02.2C</strong></td>
<td>11:25</td>
<td>Merkel cell carcinoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mahtab Samimi (Tours, France)</td>
</tr>
<tr>
<td><strong>D2T02.2D</strong></td>
<td>11:45</td>
<td>Advanced skin tumours</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Christoffer Gebhardt (Hamburg, Germany)</td>
</tr>
<tr>
<td><strong>D2T02.2E</strong></td>
<td>12:05</td>
<td>Discussion, Q&amp;A</td>
</tr>
</tbody>
</table>
### INTERACTIVE CLINICAL CASES

#### D2T02.3
- **14:00 - 15:30**
  - **STIs - clues and pitfalls in your practice**
  - *Chairs:* Electra Nicolaidou (Athens, Greece) Mihael Skerlev (Zagreb, Croatia)

#### D2T02.3A
- **14:00**
  - **Syphilis - the big imitator**
  - George Sorin Tiplica (Bucharest, Romania)

#### D2T02.3B
- **14:20**
  - **Indicator skin diseases of HIV infection**
  - Electra Nicolaidou (Athens, Greece)

#### D2T02.3C
- **14:40**
  - **Genital ulcers**
  - Mihael Skerlev (Zagreb, Croatia)

#### D2T02.3D
- **15:00**
  - **Urethritis**
  - Jonathan Krygier (Brussels, Belgium)

#### D2T02.3E
- **15:20**
  - **Discussion, Q&A**

### INTERACTIVE CLINICAL CASES

#### D2T02.4
- **15:45 - 17:15**
  - **Clinical reasoning: Residents quiz the faculty**
  - *Chair:* Antonio Torrelo (Madrid, Spain)
  - *Faculty:* Angelo Valerio Marzano (Milan, Italy) Catherine van Montfrans (Rotterdam, Netherlands) Markus Vincent Starink (Amstelveen, Netherlands) Christos C. Zouboulis (Dessau, Germany)

#### D2T02.4A
- **15:45**
  - **Pustules**
  - Maysa Sarhan (Lausanne, Switzerland)

#### D2T02.4B
- **16:05**
  - **Nodules**
  - Katarzyna Anna Pisarz (Warszawa, Poland)

#### D2T02.4C
- **16:25**
  - **Nodules**
  - Laura De Brucker (Belgium)

#### D2T02.4D
- **16:45**
  - **Ulcers**
  - Amir Samadian (Brno, Czech Republic)

#### D2T02.4E
- **17:05**
  - **Discussion, Q&A**
### Focus on SPINOLA Suite

#### D2T03.1 09:00 - 10:30

**Focus on Atopic dermatitis: Comorbidities**  
**Chairs:** Margarida Gonçalo (Coimbra, Portugal)  
Carmen Maria Salavastru (Bucharest, Romania)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Contact allergens in atopic dermatitis</td>
<td>Margarida Gonçalo (Coimbra, Portugal)</td>
</tr>
<tr>
<td>09:20</td>
<td>Infections and infestations</td>
<td>Lucinda Claire Fuller (London, United Kingdom)</td>
</tr>
<tr>
<td>09:40</td>
<td>Psychological burden</td>
<td>Marie-Aleth Richard (Marseille, France)</td>
</tr>
<tr>
<td>10:00</td>
<td>Atopic comorbidities in children</td>
<td>Carmen Maria Salavastru (Bucharest, Romania)</td>
</tr>
<tr>
<td>10:20</td>
<td>Discussion, Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

#### D2T03.2 10:45 - 12:15

**Focus on Atopic dermatitis: Therapies**  
**Chairs:** Carle Paul (Toulouse, France)  
Johannes Ring (Munich, Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45</td>
<td>Patients’ education</td>
<td>Pedro Mendes-Bastos (Lisbon, Portugal)</td>
</tr>
<tr>
<td>11:05</td>
<td>Topical therapies</td>
<td>Efstratios Vakirlis (Thessaloniki, Greece)</td>
</tr>
<tr>
<td>11:25</td>
<td>Biologics vs. JAK inhibitors</td>
<td>Carle Paul (Toulouse, France)</td>
</tr>
<tr>
<td>11:45</td>
<td>Upcoming systemic therapies</td>
<td>Johannes Ring (Munich, Germany)</td>
</tr>
<tr>
<td>12:05</td>
<td>Discussion, Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
### FOCUS ON
#### SPINOLA SUITE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Label</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td><strong>Focus on migrant dermatology and venereology: Diversity in dermatological care</strong>&lt;br&gt;Chairs: Ibrahima Traore (Conakry, Guinea) Tiago Matos (Amsterdam, Netherlands)</td>
<td>D2T03.3</td>
</tr>
<tr>
<td>14:00</td>
<td>Cultural sensitivity during STI consultation&lt;br&gt;Donia Gamoudi (Msida, Malta)</td>
<td>D2T03.3A</td>
</tr>
<tr>
<td>14:20</td>
<td>Inclusion of skin of colour images in education&lt;br&gt;Tiago Matos (Amsterdam, Netherlands)</td>
<td>D2T03.3B</td>
</tr>
<tr>
<td>14:40</td>
<td>Combining conventional and traditional medicine practices&lt;br&gt;Boon Bee Foong (Ipoh, Malaysia)</td>
<td>D2T03.3C</td>
</tr>
<tr>
<td>15:00</td>
<td>Diagnostic challenges in patients with skin of colour&lt;br&gt;Ibrahima Traore (Conakry, Guinea)</td>
<td>D2T03.3D</td>
</tr>
<tr>
<td>15:20</td>
<td>Discussion, Q&amp;A</td>
<td>D2T03.3E</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Label</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:45</td>
<td><strong>Focus on migrant dermatology and venereology: STIs in migrants</strong>&lt;br&gt;Chairs: Valeska Padovese (Valletta, Malta) Amir Mohareb (Boston, United States)</td>
<td>D2T03.4</td>
</tr>
<tr>
<td>15:45</td>
<td>HIV in migrant populations&lt;br&gt;Teymur Noori (Solna, Sweden)</td>
<td>D2T03.4A</td>
</tr>
<tr>
<td>16:05</td>
<td>STI in refugees and migrants&lt;br&gt;Amir Mohareb (Boston, United States)</td>
<td>D2T03.4B</td>
</tr>
<tr>
<td>16:25</td>
<td>Sexually-transmitted hepatitis in Europe&lt;br&gt;Anna Maria Geretti (Rome, Italy)</td>
<td>D2T03.4C</td>
</tr>
<tr>
<td>16:45</td>
<td>Public health interventions&lt;br&gt;Valeska Padovese (Valletta, Malta)</td>
<td>D2T03.4D</td>
</tr>
<tr>
<td>17:05</td>
<td>Discussion, Q&amp;A</td>
<td>D2T03.4E</td>
</tr>
</tbody>
</table>
**Scientific Programme**

**Saturday, 18 May 2024**

<table>
<thead>
<tr>
<th>ROOM</th>
<th>GRAND MASTERS SUITE</th>
<th>PORTOMASO SUITE</th>
<th>SPINOLA SUITE</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>Breaking news</td>
<td>What's new in: Hair disorders</td>
<td>Focus on migrant dermatology and venereology: Climate change and migrations</td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>Breaking news</td>
<td>What's new in: Paediatric dermatology</td>
<td>Focus on migrant dermatology and venereology: Skin signs of violence and torture</td>
</tr>
<tr>
<td>12:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Breaking news</td>
<td>What's new in: Pruritus and prurigo</td>
<td>What's new in: Bullous diseases</td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Focus on**: These sessions aim at providing comprehensive in-depth coverage of a certain topic in dermatology. The talks will be included in sessions on pathophysiology/epidemiology, clinical challenges, or practical aspects of disease management and will provide the latest cutting-edge information.

**What’s new**: These sessions will enable participants to update their knowledge on a specific topic and hear about the most relevant and recent developments, guidelines and practical knowledge from the past year. The talks will summarize the current understanding of the subject, followed by an update on the most recent novelties with their impact on clinical practice.

**Free communications**: Authors of the most highly ranked abstracts assessed by a selected panel of abstract reviewers are invited to provide a 10-minute oral presentation.

**Plenary sessions**: The Plenary lectures are EADV show-case sessions and include key-note lectures delivered by eminent scientists and doctors.

**Interactive clinical cases**: These lectures focus on a specific disease and include basic information about epidemiology, pathophysiology, diagnosis, management and prognosis. The target audience of these sessions is young dermatology trainees and residents, as well as dermatologists that want to refresh their basic knowledge on specific topics. The topic of each presentation should be developed from clinical cases and include clinical photographs. The main objective is to provide the audience clues for differential diagnosis and disease management in their daily practice. Each presentation is supposed to be interactive, with multiple-choice question made to the audience in accordance with the subjects treated in the talks. Each speaker will be asked to include 2-3 questions by “data” along with the different answers’ options.

**Breaking news**: This session type provides an update in rapidly changing fields of dermatology. It is a critical analysis of published data of last years, including new relevant information and latest development. The objective is to provide new clinically relevant and practical applicable information to be used in daily practice.
### BREAKING NEWS

**GRAND MASTERS SUITE**

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Time</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>D3T01.1</td>
<td>09:00</td>
<td><strong>Breaking news</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>09:00</td>
<td>JAK inhibitors for vitiligo</td>
<td>Albert Wolkerstorfer (Amsterdam, Netherlands)</td>
</tr>
<tr>
<td>D3T01.1A</td>
<td>09:20</td>
<td>New therapies for hidradenitis suppurativa</td>
<td>Thrasyvoulos Tzellos (Bodø, Norway)</td>
</tr>
<tr>
<td>D3T01.1B</td>
<td>09:40</td>
<td>New therapies for cutaneous lupus erythematosus</td>
<td>Branka Marinovic (Zagreb, Croatia)</td>
</tr>
<tr>
<td>D3T01.1C</td>
<td>10:00</td>
<td>New understanding and emerging therapies for chronic prurigo</td>
<td>Bernhard Homey (Düsseldorf, Germany)</td>
</tr>
<tr>
<td>D3T01.1D</td>
<td>10:20</td>
<td>Discussion, Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

### BREAKING NEWS

**GRAND MASTERS SUITE**

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Time</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>D3T01.2</td>
<td>10:45</td>
<td><strong>Breaking news</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:45</td>
<td>New therapies for genodermatoses</td>
<td>Johann Bauer (Salzburg, Austria)</td>
</tr>
<tr>
<td>D3T01.2A</td>
<td>11:05</td>
<td>What's new in aesthetic dermatology</td>
<td>Brunilda Bardhi (Tirana, Albania)</td>
</tr>
<tr>
<td>D3T01.2B</td>
<td>11:25</td>
<td>New therapies for cutaneous T-cell lymphoma</td>
<td>Evangelia Papadavid (Athens, Greece)</td>
</tr>
<tr>
<td>D3T01.2C</td>
<td>11:45</td>
<td>Microbiome in dermatology</td>
<td>Hok Bing Thio (Rotterdam, Netherlands)</td>
</tr>
<tr>
<td>D3T01.2D</td>
<td>12:05</td>
<td>Discussion, Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
### BREAKING NEWS

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>D3T01.3</td>
<td>12:30</td>
<td><strong>Breaking news</strong></td>
<td>Michel Gilliet (Lausanne, Switzerland)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Martin Röcken (Tübingen, Germany)</td>
</tr>
<tr>
<td>D3T01.3A</td>
<td>12:30</td>
<td>Expression profiling of inflammatory diseases for precision medicine</td>
<td>Michel Gilliet (Lausanne, Switzerland)</td>
</tr>
<tr>
<td>D3T01.3B</td>
<td>12:50</td>
<td>Somatic mutations in inflammatory diseases: new opportunities for precision medicine?</td>
<td>Yuval Ramot (Jerusalem, Israel)</td>
</tr>
<tr>
<td>D3T01.3C</td>
<td>13:10</td>
<td>Apps and AI: Friends or foes?</td>
<td>Tobias Sangers (Rotterdam, Netherlands)</td>
</tr>
<tr>
<td>D3T01.3D</td>
<td>13:30</td>
<td>New and emerging therapies for melanoma</td>
<td>Martin Röcken (Tübingen, Germany)</td>
</tr>
<tr>
<td>D3T01.3E</td>
<td>13:50</td>
<td>Discussion, Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

### WHAT’S NEW

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>D3T02.1</td>
<td>09:00</td>
<td><strong>What’s new in: Hair disorders</strong></td>
<td>Alexander Katoulis (Athens, Greece)</td>
</tr>
<tr>
<td>D3T02.1A</td>
<td>09:00</td>
<td>Hair disorders in children</td>
<td>Liam Mercieca (Msida, Malta)</td>
</tr>
<tr>
<td>D3T02.1B</td>
<td>09:20</td>
<td>Alopecia areata</td>
<td>Francesco Tassone (Roma, Italy)</td>
</tr>
<tr>
<td>D3T02.1C</td>
<td>09:40</td>
<td>Infections that cause hair loss</td>
<td>Giuseppe Micali (Catania, Italy)</td>
</tr>
<tr>
<td>D3T02.1D</td>
<td>10:00</td>
<td>Trichoscopy and AI</td>
<td>Alexander Katoulis (Athens, Greece)</td>
</tr>
<tr>
<td>D3T02.1E</td>
<td>10:20</td>
<td>Discussion, Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
### WHAT'S NEW

**PORTOMASO SUITE**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>D3T02.2</td>
<td>10:45</td>
<td>What's new in: Paediatric dermatology</td>
<td>Michael John Boffa (Floriana, Malta)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Carmen Maria Salavastru (Bucharest, Romania)</td>
</tr>
<tr>
<td>D3T02.2A</td>
<td>10:45</td>
<td>JAK inhibitors in adolescents</td>
<td>Marta Kurzeja (Warsaw, Poland)</td>
</tr>
<tr>
<td>D3T02.2B</td>
<td>11:05</td>
<td>Treatment of vascular lesions</td>
<td>Ketevan Khishtovani (Tbilisi, Georgia)</td>
</tr>
<tr>
<td>D3T02.2C</td>
<td>11:25</td>
<td>Autoimmune bullous diseases in children</td>
<td>Carmen Maria Salavastru (Bucharest, Romania)</td>
</tr>
<tr>
<td>D3T02.2D</td>
<td>11:45</td>
<td>Infestations</td>
<td>Michael John Boffa (Floriana, Malta)</td>
</tr>
<tr>
<td>D3T02.2E</td>
<td>12:05</td>
<td>Discussion, Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

**PORTOMASO SUITE**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>D3T02.3</td>
<td>12:30</td>
<td>What's new in: Pruritus and prurigo</td>
<td>Laurent Misery (Brest, France)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Jacek Szepietowski (Wroclaw, Poland)</td>
</tr>
<tr>
<td>D3T02.3A</td>
<td>12:30</td>
<td>Pathophysiology of itch</td>
<td>Margarida Gonçalo (Coimbra, Portugal)</td>
</tr>
<tr>
<td>D3T02.3B</td>
<td>12:50</td>
<td>Diagnostic workup of pruritus</td>
<td>Jacek Szepietowski (Wroclaw, Poland)</td>
</tr>
<tr>
<td>D3T02.3C</td>
<td>13:10</td>
<td>Classification and management of chronic prurigo</td>
<td>Bernhard Homey (Düsseldorf, Germany)</td>
</tr>
<tr>
<td>D3T02.3D</td>
<td>13:30</td>
<td>Emerging therapies for pruritus</td>
<td>Laurent Misery (Brest, France)</td>
</tr>
<tr>
<td>D3T02.3E</td>
<td>13:50</td>
<td>Discussion, Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
**Saturday, 18 May 2024**

**FOCUS ON**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| D3T03.1      | **09:00 - 10:30** Focus on migrant dermatology and venereology: Climate change and migration  
Chairs: Wendemagen Enbiale (Wageningen, Netherlands)  
Ditte Marie Saunte (Virum, Denmark)  |
| D3T03.1A     | 09:00  
WHO on climate change and migration  
Lucinda Claire Fuller (London, United Kingdom)  |
| D3T03.1B     | 09:20  
Cutaneous leishmaniasis - What are the solutions?  
Wendemagen Enbiale (Wageningen, Netherlands)  |
| D3T03.1C     | 09:40  
Strategies for epidemic fungal infections  
Ditte Marie Saunte (Virum, Denmark)  |
| D3T03.1D     | 10:00  
Strategies for epidemic scabies infestations  
Steve Walker (London, United Kingdom)  |
| D3T03.1E     | 10:20  
Discussion, Q&A  |

**FOCUS ON**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| D3T03.2      | **10:45 - 12:15** Focus on migrant dermatology and venereology: Skin signs of violence and torture  
Chairs: Patricia Deps (Vitoria, Brazil)  
Peter Greenhouse (Bristol, United Kingdom)  |
| D3T03.2A     | 10:45  
Assessing skin signs of torture  
Patricia Deps (Vitoria, Brazil)  |
| D3T03.2B     | 11:05  
Forensics in dermatology  
Coleen Kivlahan (San Francisco, United States)  |
| D3T03.2C     | 11:25  
Impact of sexual and gender-based violence on migrants health  
Isotta Rossoni (Leiden, Netherlands)  |
| D3T03.2D     | 11:45  
Rape as a weapon of war in modern conflicts  
Peter Greenhouse (Bristol, United Kingdom)  |
| D3T03.2E     | 12:05  
Discussion, Q&A  |
### What's New

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Topic</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>D3T03.3</td>
<td>12:30-14:00</td>
<td><strong>What's new in: Bullous diseases</strong></td>
<td>Dédée Murrell (Sydney, Australia) Frederic Caux (Bobigny, France)</td>
</tr>
<tr>
<td>D3T03.3A</td>
<td>12:30</td>
<td>Drug-induced bullous diseases</td>
<td>Michael Camilleri (Rochester, Minnesota, United States)</td>
</tr>
<tr>
<td>D3T03.3B</td>
<td>12:50</td>
<td>Management of Hailey-Hailey's disease</td>
<td>Dédée Murrell (Sydney, Australia)</td>
</tr>
<tr>
<td>D3T03.3C</td>
<td>13:10</td>
<td>Advances in targeted therapy</td>
<td>Frederic Caux (Bobigny, France)</td>
</tr>
<tr>
<td>D3T03.3D</td>
<td>13:30</td>
<td>Genetic disorders of skin fragility</td>
<td>Eli Sprecher (Tel Aviv, Israel)</td>
</tr>
<tr>
<td>D3T03.3E</td>
<td>13:50</td>
<td>Discussion, Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>
General information

Organiser's address and contact
European Academy of Dermatology & Venereology
Via S. Balestra 22B, 6900 Lugano - Switzerland
Website: eadv.org

Symposium venue
Hilton Malta, Portomaso Avenue, St. Julian's PTM01 - Malta
Website: hilton.com/en/hotels/mlahitw-hilton-malta

Destination management company
EC Meetings
Official booking platform: youreventbookings.com/eadv2024
Contacts: karen@ecmeetings.com - ilona@ecmeetings.com

Onsite facilities

Venue opening hours
- Thursday 16 May 08:00 – 22:00
- Friday 17 May 08:00 – 19:00
- Saturday 18 May 08:00 – 14:30

Registration area
The registration area is located on level 5 (ground level) of the Hilton Hotel - Conference Centre close to the main entrance. The registration area will be open as follows:
- Thursday 16 May 10:00 – 18:00
- Friday 17 May 08:00 – 16:00
- Saturday 18 May 08:00 – 13:00

Speaker preview room
All session rooms are equipped with LCD projection for PowerPoint presentation.
The speaker preview room is in the room Perellos, level 5 of the Hilton Hotel - Conference Centre and will be open as follows:
- Thursday 16 May 10.00 – 17.30
- Friday 17 May 08.00 – 17.30
- Saturday 18 May 08.00 – 12.30
General information

Official language
English is the official language of the Symposium. No simultaneous translation will be provided at any EADV scientific session.

Scientific sessions
Sessions of different formats will cover the important fields of dermatology and venereology. Subjects will be treated with different approaches and from different perspectives. The following session types will be scheduled throughout the duration of the Symposium and are available to all registered participants: Plenary lectures, Focus on, What's new, Clinical cases discussion, Free communications, and Breaking news.

The scientific programme has been organised on full or half-day tracks; each track has a specific topic and a structured programme. Three separate levels are offered: one junior track for Trainees and Residents, another for Board-Certified Dermatologists and Venereologists and a third one for Expert Specialists. Entry will be made on a first-come, first-served basis.

Session halls
All Scientific Session rooms for the EADV Symposium are located within the Hilton Hotel – Conference Centre and Business Centre. Please refer to the floor plans on pages 35 onwards for orientation.

Seating is regulated on a first-come, first-served basis. We recommend you go to the session room well in advance of the session to ensure your place. Due to safety regulations, the organisers will close the access to the session if all seats are occupied. Delegates are not permitted to stand in the aisles of the session rooms.

The use of mobile phones as well as audio and video recording devices are strictly prohibited within the scientific session rooms. Please ensure that you have your mobile phone switched off when attending a session. Photography is not permitted.
General information

Certificates and accreditation

All registered participants will be able to download their certificates online based on their level of engagement:

- A **Certificate of Attendance** is available for all registered participants who have a valid registration badge and attended at least 1 session.
- A **CME-CPD Certificate** is available for all participants who actively attended scientific sessions, have their badge scanned and completed the online evaluation forms.
- An **e-Poster Certificate** is available for all leading e-Poster authors.
- An **Oral presentation Certificate** is available for all presenters of an abstract accepted for an oral presentation.
- A **Speaker presentation Certificate** is available for all presenters who have delivered a lecture in a scientific session.

The certificates are not sent out automatically. They can be downloaded from our platform by entering the email address and password used during the registration process OR the EADV member log-in details (if a EADV member).

Platform URL: eadv.m-anage.com/Home/Index/Event/eadvsymposium2024/en-GB

Abstract and e-Poster

Accepted abstracts will be made available on our website eadv.org/scientific/abstract-books/

Abstracts selected for e-Posters will be published as electronic posters during the Symposium and will be available for viewing in the e-Poster area, in the Wignacourt, level 6 of the Hilton Hotel - Conference Centre. 16 big screens are provided and configured exclusively to display the e-Posters.

The e-Posters can be viewed sequentially by number, submission topic or searched individually by title, key word, or author. The e-poster area will be open as follows:

- Thursday, 16 May 11.00 – 17.30
- Friday, 17 May 8.00 – 17.30
- Saturday, 18 May 8.00 – 14.30

Information for speakers

All presentations must be in English. Speakers should also verify in the Final Programme that the name of the room and time of session have not changed.

Speakers must upload their presentation 3 hours (minimum) before the lecture if not already uploaded.

Speakers with a presentation during the first time slot of the morning are requested to upload their PowerPoint presentation the day before.
General information

Other services

Cloakroom
The cloakroom is in the Vilhena, level 6 of the Hilton Hotel - Conference Centre and will be open as follows:

- Thursday, 16 May 8.00 – 21.00
- Friday, 17 May 8.00 – 18.30
- Saturday, 18 May 8.00 – 14:30

Lost & found
Please hand in all found items and ask for lost items at the cloakroom.

Catering facilities
Lunches and coffee breaks are not included in the registration fees. Meals and snacks can be purchased within the Symposium venue during the opening hours in various catering areas of the venue. Please refer to the floor plans on pages 36 onwards for orientation.

First aid and emergency numbers
In case of need please call Emergency Malta. They are located on the Hilton’s security office ready for intervention.

Emergency numbers are:

- Emergency Malta: 112, +356 7969 8100 and +356 7969 8099

Closest hospitals to Hilton are:

- Mater Dei General Hospital - Public hospital. The emergency number in Malta is 112
- St James Private Hospital in Sliema | Telephone +356 2329 1000
General information

Privacy

Use of private data

The data made available through the Registration Portal for Congresses and Symposia are gathered and treated by the EADV in compliance with the Swiss regulation on data protection and the General Data Protection Regulation. We advise you to read full EADV Privacy Policy on eadv.org/privacy-policy.

Transferring the data to the industry session organiser

During the EADV Symposium you have the right to transfer the data collected by EADV to another controller (“the Industry session organiser”, “Industry”). It might happen through scanning a badge, QR code or other means. Each participant shall consider that by accepting any scanning of the badge, QR code or other means at any industry session at the Symposium, the participant gives authorization to the EADV to transfer the data of the participant to the Industry.

The EADV is obliged to make this process possible but does not take any responsibility for what happens with the data after it is transferred to the Industry session organiser. We advise to make sure that Industry presents Privacy Policy and read it carefully. It may occur that purposes described by the Industry Exhibitor might include the promotion of pharmaceutical products and similar.

Transfer of the data from the EADV to exhibiting Industry does not mean the removal of original data from EADV. If you wish for the data to be removed or have any request or questions, please contact us at any time by writing to eadvoffice@eadv.org.

Third-party registration

The EADV does not officially support or authorize any third-party organization that creates registrations for individuals or groups. We strongly advise to register accordingly to official fees and only on EADV official websites.

Liability disclaimer

The Organisers cannot be held liable for any hindrance or disruption to the EADV Symposium arising from political, social or economic events or any other unforeseen incidents beyond their control. The Organisers will accept no liability for any personal injuries sustained or for loss or damage to property belonging to Symposium participants, either during or as a result of the Symposium or during all tours and events. Registration of a participant entails acceptance of these conditions.
DOWNLOAD THE OFFICIAL APP

The EADV Symposium 2024 app will bring the EADV Symposium to your smartphone!

Get instant access to the full scientific programme, abstracts, e-posters, session surveys, industry sessions, and the latest news before, during and after the meeting! Interactions during sessions will be facilitated by the App, allowing you to send questions, vote and evaluate.

All you need in your hand

Scientific programme
Access the full programme and create your own agenda

Abstracts and e-Posters
Access the latest research from your device

Session evaluations
Evaluate all sessions and gain your CME-CPD credits

Interactivity
Participate to the sessions by answering the polls and ask your questions

SCAN TO LEARN MORE
or visit eadv.org/symposium/app/
The EADV Symposium 2024 will take place at the **Hilton Conference and Business Centre** in St. Julian’s, Malta.

The **Conference Centre** is the main entrance to the EADV Symposium, as it hosts the Registration Area on the level 5. Session rooms are located on level 5 and 6.

The **Business Centre** hosts one session room on level 3, while the Industry Meeting rooms and the EADV meeting rooms are located on level 2. These floors are accessible through stairs and elevators from level 5.

Conference Centre and Business Centre are connected by an internal walkway that crosses the Hilton Hotel lobby.
Venue floorplans

Conference Centre
LEVEL 5 (ground level)

REGISTRATION
SESSION ROOM
SPEAKER PREVIEW ROOM

TO / FROM BUSINESS CENTRE THROUGH HOTEL LOBBY

MAIN ENTRANCE

REGISTRATION
PERELLOS
Venue floorplans

Conference Centre
LEVEL 6

- SESSION ROOM
- EPOSTER AREA / CLOAKROOM
- EADV MEETING ROOM
- FUNCTIONS ROOM

GRAND MASTERS SUITE

VILHENA

WFNACOURT ePoster Area

Conference Centre
LEVEL 7

VERDALA

TERRACE LEVEL 7

PINTO

LEVEL 7

Escalator

Stairs

Cloakroom

Toilet

Lift

Cafeteria
Venue floorplans

Hilton Hotel Malta
**LEVEL 5** (ground level)

**NETWORKING SYMPOSIUM**
16 MAY – GAZEBO AREA
ACCESSIBLE FROM LEVEL 3
Venue floorplans

Business Centre
LEVEL 3

- SESSION ROOM
- EADV MEETING ROOMS
- INDUSTRY MEETING ROOMS

PORTOMASO SUITE

Business Centre
LEVEL 2

- Toilet
- Lift
- Cafeteria
Registration

Any person who wishes to make a registration for the EADV Symposium can proceed online (until Saturday 18 May 2024), on the registration system platform available on eadv.org/symposium/registration

Fees, deadlines, policies and other important information are published online. You can find them on the above-mentioned link.

EADV Symposium Ticket

The EADV Spring Symposium Ticket includes:

• Name badge
• Admission to EADV Scientific Sessions
• Admission to the Networking Symposium – Thursday 16 May 2024 (No entertainment)
• Access to the e-poster area
• Access to Satellite Symposia Sessions *
• Possibility to collect ECMEC Credits upon participation in the EADV Scientific Sessions

* IMPORTANT: Industry Session organisers could limit participation to certain representative groups independently from EADV recommendations if deemed imperative to the achievement of the intended purpose of the industry session. The organising company reserves the right to refuse single categories if not adequately related to the objective and purpose of the session.

A 1-Day Ticket is only valid for 1 of the 3 days of the Symposium and is limited to one ticket per participant.

Name Badge

Registered participants are invited to print out their badge at the self-printing machines on arrival to the Registration area. The name badge is the official EADV Symposium identification document and should be worn at all times in order to gain entry to the various Symposium areas.

The name badge is your ticket for booked activities and sessions. Admission to other areas of the venue is not permitted without badge identification.

The badge includes a QR-code containing your full address and email. It is the participant’s decision to disclose these details to the Industry Session’s organisers with a scanner.
Networking Symposium

Join us to celebrate the start of the 2024 EADV Symposium and participate in the first plenary lecture of this year’s edition.

The Opening Plenary Lecture will be accompanied by the welcome speech of the EADV President, Prof. Martin Röcken, who will officially inaugurate the 2024 EADV Symposium. Following his words, Prof. Charles Savona-Ventura, will present an intriguing lecture.

Starting from 18:30, a networking reception is organised at The Gazebo of the Hilton Hotel.

**Thursday, 16th May 2024**

**17:30**
Opening Plenary Lecture
Grand Masters Suite – Hilton Conference Centre level 5 [p. 38]

**18:30**
Networking Reception
The Gazebo - Hilton Hotel level 5 [p. 37]
Healthcare Professional information and definition

EADV Members are not designated as healthcare professionals by default.

According to the European Union Directive 2001/83 /EC (and amended version 2010/84/EU), the promotion of prescription only medicines should be directed solely at Healthcare Professionals or any person who is authorised to prescribe or handle them.

As a multidisciplinary audience will be attending the EADV Symposium, the delegates must indicate if they are Healthcare Professionals (HCP) or Non-Healthcare Professionals (Non-HCP) to ensure compliance with these regulations.

Access to the different areas and sessions of the Symposium depends on the status as Healthcare Professional or as Non-Healthcare Professional.

The Pharmaceutical Research Based Industry Malta Association (2014) defines HCP as: “Any member of the medical, dental, pharmacy or nursing professions or any other person who during his or her professional activities may prescribe, purchase, supply or administer a medicinal product.”

Industry sessions and advertising

Sections of the code also relevant to a congress held in Malta: “Any such promotional material (excluding promotional aids) is accompanied by a suitable statement indicating countries in which the product is registered and makes clear that the product or use is not registered locally, and any such promotional material which refers to the prescribing information (indications, warnings etc.) authorized in a country or countries where the medicinal product is registered should be accompanied by an explanatory statement indicating that registration conditions differ internationally.”

Satellite Symposia presenting data on the development, research or other issues related to prescription medicine can be restricted to Healthcare Professionals and Industry Participants only upon indication provided by the Industry Session Organizer. All promotional materials and marketing aids related to these industry sessions should be strictly limited to HCPs only.

Industry Session organisers could limit participation to certain representative groups independently from the EADV recommendations if deemed imperative to the achievement of the intended purpose of the Industry session. The organising company reserves the right to refuse single categories, if not adequately related to the objective and purpose of the session. The industry session organizer is responsible for the compliance of the session.

Other categories

STUDENTS are NOT considered as Healthcare Professionals under the current guidelines and will be automatically classified as NON-HEALTHCARE PROFESSIONALS.
Industry Sessions and Details
Industry sessions

Industry sessions programme

We invite you to discover the official industry sessions programme during the EADV Symposium 2024.

Three Satellite Symposia are organised on 16 and 17 May 2024.

The industry sessions offer a unique opportunity to connect with key thought leaders, access to information on emerging science and innovative approaches to a wide range of current medical topics.

For industry session details, review the following pages or download the full Industry Sessions Programme Booklet.

Satellite symposia programme and faculty in particular

The Industry Session organiser is solely responsible for keeping all of its Industry Session activities compliant with all relevant laws and regulations. EADV is not involved with or has any control over the content, quality, organisation, operation, or scientific integrity of the activity and materials provided by the industries. EADV is not involved in the selection of speakers, moderators, and other faculty.

Access to satellite symposia

As a multidisciplinary audience will be attending the EADV Symposium 2024, please make sure to select the right category: Healthcare Professionals (HCPs) or Non-Healthcare Professionals (NON-HCPs), during the registration process.

Access to any Industry Sessions where data or research on prescription medicines is presented will be limited to Healthcare Professionals (HCPs) and Non Members (INDUSTRY).

Industry Session organisers may limit participation to certain representative groups independently from EADV recommendations if deemed imperative to the achievement of the intended purpose of the Industry Session.
Scratching beneath the surface: A deeper understanding of AD and PN

Thursday, 16th May 2024, 12:45-13:45 CEST,
St. Julian’s, Malta
Hilton Conference Center – SPINOLA SUITE

Learning objectives are:
- Describe the common and different clinical manifestations, patient burden and treatment objectives for Atopic Dermatitis (AD) and Prurigo Nodularis (PN)
- Discuss the role of type 2 inflammation in both diseases
- Explore the benefits of targeting IL-4 and IL-13 signaling with dupilumab in AD and PN

AGENDA

<table>
<thead>
<tr>
<th>Minutes</th>
<th>Session Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>Welcome</td>
<td>P. Bastos</td>
</tr>
<tr>
<td>10</td>
<td>AD and PN: Distinct diseases with common drivers</td>
<td>E. Kiracofe</td>
</tr>
<tr>
<td>10</td>
<td>IL-4 and IL-13, key drivers of type 2 inflammation and underlying pathophysiology in AD and PN</td>
<td>P. Bastos</td>
</tr>
<tr>
<td>20</td>
<td>Dual inhibition of IL-4 and IL-13 signalling: Achieving disease control in both AD and PN</td>
<td>All faculty</td>
</tr>
<tr>
<td>10</td>
<td>Q&amp;A</td>
<td>All faculty</td>
</tr>
<tr>
<td>5</td>
<td>Close</td>
<td></td>
</tr>
</tbody>
</table>

This session is restricted to Healthcare Professionals only. MAT-GLB-2400474 V1 05/2024.
© 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
### Satellite symposia

**Thursday 16 May 2024**

**12:45 - 13:45**  
**HCPs Only**

**Scratching beneath the surface: A deeper understanding of AD and PN**

**Sanofi and Regeneron**

**ROOM:** Spinola Suite  
**CODE:** SAT 02  
**CHAIR:** Pedro Bastos (Lisbon, Portugal)

<table>
<thead>
<tr>
<th>CODE</th>
<th>TIME</th>
<th>PROGRAMME</th>
</tr>
</thead>
</table>
| SAT 02.01 | 12:45  | **Welcome**  
Pedro Bastos (Lisbon, Portugal) |
| SAT 02.02 | 12:50  | **AD and PN: Distinct diseases with common drivers**  
Elizabeth Kiracofe (Chicago, United States) |
| SAT 02.03 | 13:00  | **IL-4 and IL-13, key drivers of type 2 inflammation and underlying pathophysiology in AD and PN**  
Pedro Bastos (Lisbon, Portugal) |
| SAT 02.04 | 13:10  | **Dual inhibition of IL-4 and IL-13 signaling: Achieving disease control in both AD and PN patients**  
Pedro Bastos (Lisbon, Portugal)  
Elizabeth Kiracofe (Chicago, United States) |
| SAT 02.05 | 13:30  | **Q&A**  
Pedro Bastos (Lisbon, Portugal)  
Elizabeth Kiracofe (Chicago, United States) |
| SAT 02.06 | 13:40  | **Close**  
Pedro Bastos (Lisbon, Portugal)  
Elizabeth Kiracofe (Chicago, United States) |
# Satellite symposia

**Friday 17 May 2024**

<table>
<thead>
<tr>
<th>CODE</th>
<th>TIME</th>
<th>PROGRAMME</th>
</tr>
</thead>
</table>
| SAT 05.01 | 12:45 | **Welcome and Introduction**  
Jacek C. Szepietowski (Wroclaw, Poland)  |
| SAT 05.02 | 12:50 | **Rapid and Sustained Itch Relief Are Key to Patient Satisfaction**  
Laura Savage (Leeds, United Kingdom)  |
| SAT 05.03 | 13:15 | **Integrating the Latest Advances Into Your AD Practice**  
Jacek C. Szepietowski (Wroclaw, Poland)  |
| SAT 05.04 | 13:35 | **Summary and conclusion**  
Jacek C. Szepietowski (Wroclaw, Poland)  |
| SAT 05.05 | 13:40 | **Q&A**  
Jacek C. Szepietowski (Wroclaw, Poland)  
Laura Savage (Leeds, United Kingdom)  |
We’re inspired by a single vision:

Transforming patients’ lives through science™

Bristol Myers Squibb™

© 2024 Bristol-Myers Squibb Company. IMM-ELR-2400001 3/24
## Satellite symposia

**Friday 17 May 2024**

<table>
<thead>
<tr>
<th>CODE</th>
<th>TIME</th>
<th>PROGRAMME</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAT 06.01</td>
<td>12:45</td>
<td>Welcome and Introduction</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tiago Torres (Porto, Portugal)</td>
</tr>
<tr>
<td>SAT 06.02</td>
<td>12:50</td>
<td>Disease Burden and Unmet Needs in Psoriasis: Lessons From Real-World Data</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lluís Puig (Barcelona, Spain)</td>
</tr>
<tr>
<td>SAT 06.03</td>
<td>13:00</td>
<td>The Role of TYK2 in the IL-23/IL-17 Inflammatory Axis and Psoriasis Pathogenesis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carle Paul (Toulouse, France)</td>
</tr>
<tr>
<td>SAT 06.04</td>
<td>13:15</td>
<td>From Conventional Broad acting Agents to New class Targeted TYK2 Inhibitors in PsO</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tiago Torres (Porto, Portugal)</td>
</tr>
<tr>
<td>SAT 06.05</td>
<td>13:35</td>
<td>Summary and conclusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tiago Torres (Porto, Portugal) Carle Paul (Toulouse, France) Lluís Puig (Barcelona, Spain)</td>
</tr>
</tbody>
</table>
Participating companies

**Sanofi**

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

[Sanofi](sanofi.com)

**Regeneron**

Regeneron is a leading biotechnology company that invents medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments, almost all of which were homegrown in our laboratories.

[Regeneron](www.regeneron.com)

**Pfizer**


At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

[Francesca Molisso](francesca.molisso@pfizer.com)

[www.pfizer.com](www.pfizer.com)

**Bristol Myers Squibb**

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science.

[Medical Communications](medical.communications@bms.com)

[www.bms.com](www.bms.com)
BRIDGE TO THE FUTURE

AMSTERDAM
25-28 SEPTEMBER 2024

REGISTER NOW
eadv.org/congress